Skip to main content
Erschienen in: Obesity Surgery 5/2017

03.11.2016 | Original Contributions

Serum Plant Sterols Associate with Gallstone Disease Independent of Weight Loss and Non-Alcoholic Fatty Liver Disease

verfasst von: Pirjo Käkelä, Ville Männistö, Imre Ilves, Maija Vaittinen, Milla-Maria Tauriainen, Matti Eskelinen, Helena Gylling, Hannu Paajanen, Jussi Pihlajamäki

Erschienen in: Obesity Surgery | Ausgabe 5/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Gallstone disease (GD) has been associated with low serum levels of plant sterols. We evaluated the impact of laparoscopic Roux-en-Y gastric bypass (LRYGB) and non-alcoholic fatty liver disease (NAFLD) on the association of GD with low levels of serum plant sterols.

Methods

Two hundred forty-two consecutive morbidly obese patients were recruited to this prospective study. Histological analysis of liver biopsy to diagnose NAFLD was performed. Bile sample was taken during the LRYGB. Associations of GD with serum non-cholesterol sterol to cholesterol ratios, measured using gas liquid chromatography and with mRNA expression of genes participating in the cholesterol, bile, and fatty acid metabolism in the liver, were analyzed.

Results

Out of the 242 participants, 95 had GD. Lower weight (p = 0.002) and female sex (p = 0.0006) were associated with GD. Serum plant sterols, campesterol (p = 0.003), sitosterol (p = 0.002), and avenasterol (p = 0.015), were lower in patients with GD compared to those without GD. This association remained significant after adjustment for NAFLD, use of statin medication, and previous laparoscopic cholecystectomy (LCC). Levels of sitosterol (p = 0.001) and campesterol (p = 0.001) remained lower in obese individuals with GD also after obesity surgery. Liver mRNA expression of genes regulating cholesterol synthesis and bile metabolism was increased in individuals with GD.

Conclusions

Serum plant sterols were lower in patients with GD independent of NAFLD, history of LCC, use of statin medication, and weight loss after LRYGB. Low serum plant sterols in patients with GD suggest potentially inherited alterations in sterol absorption and biliary transport in subjects susceptible for GD.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Shaffer EA. Gallstone disease: epidemiology of gallbladder stone disease. Best Pract Res Clin Gastroenterol. 2006;20(6):981–96.CrossRefPubMed Shaffer EA. Gallstone disease: epidemiology of gallbladder stone disease. Best Pract Res Clin Gastroenterol. 2006;20(6):981–96.CrossRefPubMed
2.
Zurück zum Zitat Abrams GA, Kunde SS, Lazenby AJ, et al. Portal fibrosis and hepatic steatosis in morbidly obese subjects: a spectrum of nonalcoholic fatty liver disease. Hepatology. 2004;40(2):475–83.CrossRefPubMed Abrams GA, Kunde SS, Lazenby AJ, et al. Portal fibrosis and hepatic steatosis in morbidly obese subjects: a spectrum of nonalcoholic fatty liver disease. Hepatology. 2004;40(2):475–83.CrossRefPubMed
3.
Zurück zum Zitat Xanthakos S, Miles L, Bucuvalas J, et al. Histologic spectrum of nonalcoholic fatty liver disease in morbidly obese adolescents. Clin Gastroenterol Hepatol. 2006;4(2):226–32.CrossRefPubMed Xanthakos S, Miles L, Bucuvalas J, et al. Histologic spectrum of nonalcoholic fatty liver disease in morbidly obese adolescents. Clin Gastroenterol Hepatol. 2006;4(2):226–32.CrossRefPubMed
5.
Zurück zum Zitat Loria P, Lonardo A, Lombardini S, et al. Gallstone disease in non-alcoholic fatty liver: prevalence and associated factors. J Gastroenterol Hepatol. 2005;20:1176–84.CrossRefPubMed Loria P, Lonardo A, Lombardini S, et al. Gallstone disease in non-alcoholic fatty liver: prevalence and associated factors. J Gastroenterol Hepatol. 2005;20:1176–84.CrossRefPubMed
6.
Zurück zum Zitat Fracanzani AL, Valenti L, Russello M, et al. Gallstone disease is associated with more severe liver damage in patients with non-alcoholic fatty liver disease. PLoS One. 2012;7(7):e41183.CrossRefPubMedPubMedCentral Fracanzani AL, Valenti L, Russello M, et al. Gallstone disease is associated with more severe liver damage in patients with non-alcoholic fatty liver disease. PLoS One. 2012;7(7):e41183.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Roesch-Dietlen F, Pérez-Morales A, Melo-Santisteban G, et al. Frequency and clinical, biochemical and histological characteristics of nonalcoholic fatty liver disease in patients with gallstone disease. Cir Cir. 2008;76:37–42.PubMed Roesch-Dietlen F, Pérez-Morales A, Melo-Santisteban G, et al. Frequency and clinical, biochemical and histological characteristics of nonalcoholic fatty liver disease in patients with gallstone disease. Cir Cir. 2008;76:37–42.PubMed
8.
Zurück zum Zitat la Ramos-De MA, Remes-Troche JM, Roesch-Dietlen FB, et al. Routine liver biopsy to screen for nonalcoholic fatty liver disease (NAFLD) during cholecystectomy for gallstone disease: is it justified? J Gastrointest Surg. 2008;12:2097–102.CrossRef la Ramos-De MA, Remes-Troche JM, Roesch-Dietlen FB, et al. Routine liver biopsy to screen for nonalcoholic fatty liver disease (NAFLD) during cholecystectomy for gallstone disease: is it justified? J Gastrointest Surg. 2008;12:2097–102.CrossRef
9.
Zurück zum Zitat Krawczyk M, Bonfrate L, Portincasa P. Nonalcoholic fatty liver disease. Best Pract Res Clin Gastroenterol. 2010;24:695–708.CrossRefPubMed Krawczyk M, Bonfrate L, Portincasa P. Nonalcoholic fatty liver disease. Best Pract Res Clin Gastroenterol. 2010;24:695–708.CrossRefPubMed
10.
Zurück zum Zitat Koller T, Kollerova J, Hlavaty T, et al. Cholelithiasis and markers of nonalcoholic fatty liver disease in patients with metabolic risk factors. Scand J Gastroenterol. 2012;47:197–203.CrossRefPubMed Koller T, Kollerova J, Hlavaty T, et al. Cholelithiasis and markers of nonalcoholic fatty liver disease in patients with metabolic risk factors. Scand J Gastroenterol. 2012;47:197–203.CrossRefPubMed
11.
Zurück zum Zitat Krawczyk M, Lütjohann D, Schirin-Sokhan R, et al. Phytosterol and cholesterol precursor levels indicate increased cholesterol excretion and biosynthesis in gallstone disease. Hepatology. 2012 May;55(5):1507–17. doi:10.1002/hep.25563.CrossRefPubMed Krawczyk M, Lütjohann D, Schirin-Sokhan R, et al. Phytosterol and cholesterol precursor levels indicate increased cholesterol excretion and biosynthesis in gallstone disease. Hepatology. 2012 May;55(5):1507–17. doi:10.​1002/​hep.​25563.CrossRefPubMed
12.
Zurück zum Zitat Simonen P, Kotronen A, Hallikainen M, et al. Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity. J Hepatol. 2011;54:153–9.CrossRefPubMed Simonen P, Kotronen A, Hallikainen M, et al. Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity. J Hepatol. 2011;54:153–9.CrossRefPubMed
13.
Zurück zum Zitat Cariati A, Piromalli E. Limits and perspective of oral therapy with statins and aspirin for the prevention of symptomatic cholesterol gallstone disease. Expert Opin Pharmacother. 2012;13(9):1223–7.CrossRefPubMed Cariati A, Piromalli E. Limits and perspective of oral therapy with statins and aspirin for the prevention of symptomatic cholesterol gallstone disease. Expert Opin Pharmacother. 2012;13(9):1223–7.CrossRefPubMed
14.
Zurück zum Zitat Miettinen TA, Tilvis RS, Kesäniemi YA. Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. Am J Epidemiol. 1990;131:20–31.CrossRefPubMed Miettinen TA, Tilvis RS, Kesäniemi YA. Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. Am J Epidemiol. 1990;131:20–31.CrossRefPubMed
15.
Zurück zum Zitat Temel RE, Tang W, Ma Y, et al. Hepatic Niemann-pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J Clin Invest. 2007;117(7):1968–78.CrossRefPubMedPubMedCentral Temel RE, Tang W, Ma Y, et al. Hepatic Niemann-pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J Clin Invest. 2007;117(7):1968–78.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Berge KE, Tian H, Graf GA, et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science. 2000;290(5497):1771–5.CrossRefPubMed Berge KE, Tian H, Graf GA, et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science. 2000;290(5497):1771–5.CrossRefPubMed
17.
Zurück zum Zitat Renner O, Lütjohann D, Richter D, et al. Role of the ABCG8 19H risk allele in cholesterol absorption and gallstone disease. BMC Gastroenterol. 2013;13:30.CrossRefPubMedPubMedCentral Renner O, Lütjohann D, Richter D, et al. Role of the ABCG8 19H risk allele in cholesterol absorption and gallstone disease. BMC Gastroenterol. 2013;13:30.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Krawczyk M, Wang DQ, Portincasa P, et al. Dissecting the genetic heterogeneity of gallbladder stone formation. Semin Liver Dis. 2011;31:157–72.CrossRefPubMed Krawczyk M, Wang DQ, Portincasa P, et al. Dissecting the genetic heterogeneity of gallbladder stone formation. Semin Liver Dis. 2011;31:157–72.CrossRefPubMed
19.
Zurück zum Zitat Buch S, Schafmayer C, Völzke H, et al. A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease. Nat Gen. 2007;39:995–9.CrossRef Buch S, Schafmayer C, Völzke H, et al. A genome-wide association scan identifies the hepatic cholesterol transporter ABCG8 as a susceptibility factor for human gallstone disease. Nat Gen. 2007;39:995–9.CrossRef
20.
Zurück zum Zitat Grunhage F, Acalovschi M, Tirziu S, et al. Increased gallstone risk in humans conferred by common variant of hepatic ATP-binding cassette transporter for cholesterol. Hepatology. 2007;46:793–801.CrossRefPubMed Grunhage F, Acalovschi M, Tirziu S, et al. Increased gallstone risk in humans conferred by common variant of hepatic ATP-binding cassette transporter for cholesterol. Hepatology. 2007;46:793–801.CrossRefPubMed
23.
Zurück zum Zitat Pihlajamäki J, Kuulasmaa T, Kaminska D, et al. Serum interleukin 1 receptor antagonist as an independent marker of nonalcoholic steatohepatitis in humans. Int J Hepatol. 2012;3:663–70.CrossRef Pihlajamäki J, Kuulasmaa T, Kaminska D, et al. Serum interleukin 1 receptor antagonist as an independent marker of nonalcoholic steatohepatitis in humans. Int J Hepatol. 2012;3:663–70.CrossRef
24.
Zurück zum Zitat Conference NIH. Gastrointestinal surgery for severe obesity. Consensus development conference panel. Ann Intern Med. 1991;115:956–61.CrossRef Conference NIH. Gastrointestinal surgery for severe obesity. Consensus development conference panel. Ann Intern Med. 1991;115:956–61.CrossRef
25.
Zurück zum Zitat Chiang WK, Lee FM, Santen S. Cholelithiasis. eMedicine. November 3, 2009. accessed, November 30, 2009. Chiang WK, Lee FM, Santen S. Cholelithiasis. eMedicine. November 3, 2009. accessed, November 30, 2009.
26.
Zurück zum Zitat American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2004;27:5–10.CrossRef American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2004;27:5–10.CrossRef
27.
Zurück zum Zitat Miettinen TA. Cholesterol metabolism during ketoconazole treatment in man. J Lipid Res. 1988;29:43–51.PubMed Miettinen TA. Cholesterol metabolism during ketoconazole treatment in man. J Lipid Res. 1988;29:43–51.PubMed
28.
Zurück zum Zitat Simonen P, Gylling H, Miettinen TA. The validity of serum squalene and non-cholesterol sterols as surrogate markers of cholesterol synthesis and absorption in type 2 diabetes. Atherosclerosis. 2008;197:883–8.CrossRefPubMed Simonen P, Gylling H, Miettinen TA. The validity of serum squalene and non-cholesterol sterols as surrogate markers of cholesterol synthesis and absorption in type 2 diabetes. Atherosclerosis. 2008;197:883–8.CrossRefPubMed
29.
Zurück zum Zitat Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–74.CrossRefPubMed Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999;94:2467–74.CrossRefPubMed
30.
Zurück zum Zitat Barrera F, Azócar L, Molina H, et al. Effect of cholecystectomy on bile acid synthesis and circulating levels of fibroblast growth factor 19. Ann Hepatol. 2015;14(5):710–21.PubMed Barrera F, Azócar L, Molina H, et al. Effect of cholecystectomy on bile acid synthesis and circulating levels of fibroblast growth factor 19. Ann Hepatol. 2015;14(5):710–21.PubMed
31.
Zurück zum Zitat Lammert F, Wang DQ. New insights into the genetic regulation of intestinal cholesterol absorption. Gastroenterology. 2005;129:718–34.CrossRefPubMed Lammert F, Wang DQ. New insights into the genetic regulation of intestinal cholesterol absorption. Gastroenterology. 2005;129:718–34.CrossRefPubMed
32.
Zurück zum Zitat Jiang ZY, Parini P, Eggertsen G, et al. Increased expression of LXR alpha, ABCG5, ABCG8, and SR-BI in the liver from normolipidemic, nonobese Chinese gallstone patients. J Lipid Res. 2008;49:464–72.CrossRefPubMed Jiang ZY, Parini P, Eggertsen G, et al. Increased expression of LXR alpha, ABCG5, ABCG8, and SR-BI in the liver from normolipidemic, nonobese Chinese gallstone patients. J Lipid Res. 2008;49:464–72.CrossRefPubMed
33.
Zurück zum Zitat Kosters A, Frijters RJ, Schaap FG, et al. Relation between hepatic expression of ATP-binding cassette transporters G5 and G8 and biliary cholesterol secretion in mice. J Hepatol. 2003;38:710–6.CrossRefPubMed Kosters A, Frijters RJ, Schaap FG, et al. Relation between hepatic expression of ATP-binding cassette transporters G5 and G8 and biliary cholesterol secretion in mice. J Hepatol. 2003;38:710–6.CrossRefPubMed
34.
Zurück zum Zitat Kamisako T, Ogawa H. Regulation of biliary cholesterol secretion is associated with abcg5 and abcg8 expressions in the rats: effects of diosgenin and ethinyl estradiol. Hepatol Res. 2003;26:348–52.CrossRefPubMed Kamisako T, Ogawa H. Regulation of biliary cholesterol secretion is associated with abcg5 and abcg8 expressions in the rats: effects of diosgenin and ethinyl estradiol. Hepatol Res. 2003;26:348–52.CrossRefPubMed
38.
Zurück zum Zitat Smit JW, van Erpecum KJ, Stolk MF, et al. Successful dissolution of cholesterol gallstone during treatment with pravastatin. Gastroenterology. 1992;103:1068–70.CrossRefPubMed Smit JW, van Erpecum KJ, Stolk MF, et al. Successful dissolution of cholesterol gallstone during treatment with pravastatin. Gastroenterology. 1992;103:1068–70.CrossRefPubMed
39.
Zurück zum Zitat HH W, Portincasa P, de Bari O, et al. Prevention of cholesterol gallstones by inhibiting hepatic biosynthesis and intestinal absorption of cholesterol. Eur J Clin Investig. 2013;43(4):413–26.CrossRef HH W, Portincasa P, de Bari O, et al. Prevention of cholesterol gallstones by inhibiting hepatic biosynthesis and intestinal absorption of cholesterol. Eur J Clin Investig. 2013;43(4):413–26.CrossRef
40.
Zurück zum Zitat Gurusamy KS, Davidson BR. Surgical treatment of gallstones. Gastroenterol Clin N Am. 2010;39(2):229–44.CrossRef Gurusamy KS, Davidson BR. Surgical treatment of gallstones. Gastroenterol Clin N Am. 2010;39(2):229–44.CrossRef
41.
Zurück zum Zitat Portincasa P, Moschetta A, Palasciano G. Cholesterol gallstone disease. Lancet. 2006;368(9531):230–9.CrossRefPubMed Portincasa P, Moschetta A, Palasciano G. Cholesterol gallstone disease. Lancet. 2006;368(9531):230–9.CrossRefPubMed
42.
Zurück zum Zitat Bodmer M, Brauchli YB, Krahenbuhl S, et al. Statin use and risk of gallstone disease followed by cholecystectomy. JAMA. 2009;302(18):2001–7.CrossRefPubMed Bodmer M, Brauchli YB, Krahenbuhl S, et al. Statin use and risk of gallstone disease followed by cholecystectomy. JAMA. 2009;302(18):2001–7.CrossRefPubMed
43.
Metadaten
Titel
Serum Plant Sterols Associate with Gallstone Disease Independent of Weight Loss and Non-Alcoholic Fatty Liver Disease
verfasst von
Pirjo Käkelä
Ville Männistö
Imre Ilves
Maija Vaittinen
Milla-Maria Tauriainen
Matti Eskelinen
Helena Gylling
Hannu Paajanen
Jussi Pihlajamäki
Publikationsdatum
03.11.2016
Verlag
Springer US
Erschienen in
Obesity Surgery / Ausgabe 5/2017
Print ISSN: 0960-8923
Elektronische ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-016-2446-z

Weitere Artikel der Ausgabe 5/2017

Obesity Surgery 5/2017 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.